Search for content, post, videos

CEO Geoffrey McDonough to leave Sobi

sobi ceo

Swedish Orphan Biovitrum announces that Geoffrey McDonough will leave Sobi on 1 July 2017, and that a search for a new Chief Executive Officer has been initiated to identify his successor.

“Geoffrey McDonough has created remarkable value in his term as CEO. Under his leadership Sobi has become a prominent rare disease biotech company with a vibrant and growing commercial portfolio and significant growth potential ahead”, says Håkan Björklund, Chairman of the Board of Sobi, “Given the increasing demand and focus of our business in Europe, the Board has decided that Sobi needs more continuous presence in Stockholm than Geoffrey can sustain given his current location in Boston.”

“Sobi stands today on the platform of a strong and unique rare disease position supported by several years of strong financial results”, says Geoffrey McDonough, CEO and President of Sobi, “The Company is entering a period of unprecedented growth and opportunity that will benefit from local leadership.”